Pharmacovigilance – News and Features

Researchers are learning to control proteins in a new way.

Focuses on stabilization of unstable molecules expands drug delivery base for proteins and peptides.

Pharsight will collaborate with the FDA using Pharsight software for the analysis, visualization, storage, reporting and review of pharmacokinetic/pharmacodynamic data.

Company licenses intellectual property relating to genetic testing for warfarin response.

Validated library of monoclonal antibodies is a major step toward personalized chemotherapy management.

Collaboration to establish optimal protocols for isolating cord blood cells.

The study was intended to test the limits of RNAi expression with respect to safety and efficacy.

Studies demonstrated that injecting stem cells into the urethral muscles increases leak point pressure.

If RNAi is going to be viable as a therapy for organ-wide diseases such as hepatitis B or C, it will have to stick around.

This trial is important because it is one of the first to examine a methodology for personalizing cancer treatment.